Investments – LSI Zeta

CubaseBio enables true 3D spatial analysis at scale, unlocking unprecedented biological insights and accelerating drug discovery.

Specializing in the development of next generation single domain antibodies. Mesenkia is a pre-clinical company developing the next-generation biological drug candidates designed to treat the aggressive brain tumor glioblastoma.